Welcome to our dedicated page for Breeze Holdings Acquisition news (Ticker: BREZ), a resource for investors and traders seeking the latest updates and insights on Breeze Holdings Acquisition stock.
Breeze Holdings Acquisition Corp. (historically associated with the symbol BREZ) generated news primarily as a special purpose acquisition company working to complete business combinations rather than as an operating business. Its press releases and SEC-referenced announcements focus on merger agreements, stockholder votes, listing status, and the transition of value to the operating companies it sought to combine with.
News coverage for Breeze includes multiple stages of proposed transactions. Earlier releases describe a business combination agreement with TV Ammo, Inc., also known as True Velocity, an advanced technology and composite manufacturing company focused on composite-cased ammunition, weapon systems, and suppressors. These items highlight the filing of a registration statement on Form S-4, conference participation, and transaction timelines.
Subsequent news documents a shift in strategy, including the termination of the TV Ammo business combination and Breeze’s stated intention to continue pursuing another target. Later, Breeze announced a definitive agreement to merge with YD Biopharma Limited, a clinical-stage biopharmaceutical company concentrating on cancer prevention medical diagnostics and exosome-based therapeutics. Follow-up releases detail patents and authorizations obtained by YD Biopharma, as well as the structure and expected listing of the combined company on the Nasdaq Capital Market.
More recent news reports that Breeze stockholders approved the business combination with YD Biopharma at a special meeting, with the combined company to be named YD Bio Limited and its ordinary shares expected to trade under the ticker “YDES.” Other items cover extensions of the SPAC’s business combination deadline, movement of its securities to OTCQX and OTCQB markets, and updates on trust account redemptions.
Investors and researchers using this news page can review the full sequence of announcements around BREZ, including transaction milestones, regulatory filings referenced in the releases, and the evolution from an initial SPAC listing to an approved merger with a biopharmaceutical company. This historical news record helps explain how Breeze’s capital and listing structure were used to support its chosen combination partners.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) shareholders have approved the business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company focused on vaccines and therapeutic biologics. The special meeting saw 3,128,495 shares represented, with 3,127,474 shares voting in favor of the merger.
The combined entity will be renamed to YD Bio Limited and is expected to trade on the Nasdaq under the ticker symbol "YDES". The transaction is anticipated to close within two weeks, pending customary closing conditions.
Breeze Holdings Acquisition Corp (OTCQX: BRZH) has entered into a definitive agreement to merge with YD Biopharma , a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and exosome-based therapeutics. The combined company, with an estimated enterprise value of nearly $700 million, is expected to be listed on the Nasdaq Capital Market by early 2025.
YD Biopharma has recently obtained patents, technology, and U.S. authorization for core methylation detection of pancreatic cancer, and is in the process of acquiring licenses for breast cancer detection technology. The company also specializes in ophthalmology cellular drug development and serves as a clinical testing drug supplier for Novartis.
The transaction, approved by both companies' boards, aims to provide YD Biopharma with capital to expand production and continue development, approval, and launch of new technologies. The combined company will be led by YD Biopharma's current management team.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) has announced its approval to trade on the OTCQX Best Market. The company's common stock and warrants, under tickers 'BRZH' and 'BRZHW' respectively, began trading on August 21, 2024. This update follows the termination of a previously planned business combination with TV Ammo, Inc., as reported in a Form 8-K filing on August 9, 2024.
Breeze's management team is actively pursuing a new business combination transaction and has until December 26, 2024 to complete one, as per SEC requirements. The company plans to provide further updates as progress is made in identifying a potential target company.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Breeze Holdings Acquisition (BREZ)?
What is the market cap of Breeze Holdings Acquisition (BREZ)?
